中等乳腺癌风险人群筛查中磁共振乳腺成像与传统乳腺X线摄影的成本效果分析:基于模型的经济学评价
本研究基于已发表文献参数构建决策模型与马尔可夫模型,在30年时间框架内比较磁共振乳腺成像(MRM)与传统乳腺X线摄影(XM)筛查中等乳腺癌风险人群的累积成本与质量调整生命年。XM总成本5492.68美元、累积18.87 QALYs,MRM总成本5878.66美元、累积18.92 QALYs,MRM的增量成本效果比为每QALY 8797.60美元,明显低于国际支付意愿阈值,敏感性分析支持该结果。作者认为,对于因乳腺组织致密而处于中等乳腺癌风险的患者,每两年一次MRM筛查可能具有成本效果。
要点
- 中等风险(乳腺组织致密)人群每两年一次MRM筛查的ICER为每QALY 8797.60美元。
- 该ICER明显低于国际支付意愿阈值,确定性及概率敏感性分析(30000次蒙特卡洛迭代)支持模型稳定。
核心结论
- 对于因乳腺组织致密而处于中等乳腺癌风险的患者,每两年一次MRM筛查可能具有成本效果。
研究设计与样本
- 基于模型的经济学评价:构建两种诊断模式的决策模型及模拟随访成本与结局的马尔可夫模型,输入参数取自已发表文献。
- 在30年时间框架内以美元和QALYs计算两种模式的期望累积成本与结局。
- 进行确定性敏感性分析及包含30000次蒙特卡洛迭代的概率敏感性分析以考察模型稳定性。
诊断标准与关键数值
- XM组总成本5492.68美元、平均累积生活质量18.87 QALYs;MRM组总成本5878.66美元、18.92 QALYs。
- MRM的增量成本效果比(ICER)为每QALY 8797.60美元,明显低于国际支付意愿阈值。
- 结果在敏感性分析的范围内得到确认。
临床应用与阅片要点
- 作者认为,对因乳腺组织致密而处于中等乳腺癌风险的患者,每两年一次MRM筛查可能具有成本效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The aim of this study was to analyze the cost-effectiveness of screening patients of intermediate risk of breast cancer with MR-Mammography (MRM) versus conventional mammography (XM).
METHOD: A decision model for both diagnostic modalities and a subsequent markov model for the simulation of follow-up costs and outcomes was developed. Input parameters were acquired from published literature for this markov modelling study. The expected cumulative costs and outcomes were calculated for both modalities in a 30-year timeframe in US-dollar ($) and quality-adjusted life years (QALYs). A deterministic sensitivity analysis and a probabilistic sensitivity analysis incorporating 30,000 Monte Carlo iterations were performed to investigate the model stability.
RESULTS: In total, XM with its consecutive treatments resulted in total costs of $ 5,492.68 and an average cumulative quality of life of 18.87 QALYs, compared to MRM with costs of $ 5,878.66 and 18.92 QALYs. The corresponding incremental cost-effectiveness ratio (ICER) for MRM was $ 8,797.60 per QALY - distinctly below international willingness-to-pay thresholds for cost-effectiveness. The results were confirmed within the limits of the sensitivity analyses.
CONCLUSIONS: In patients with intermediate risk for breast cancer due to their dense breast tissue, two-yearly screening with MRM may be considered as cost-effective.
引用
- Kaiser CG, Dietzel M, Vag T, et al. Cost-effectiveness of MR-mammography vs. conventional mammography in screening patients at intermediate risk of breast cancer - A model-based economic evaluation. Eur J Radiol. 2020. PMID: 33214003. doi:10.1016/j.ejrad.2020.109355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。